Complement Component 3 (C3)

[Edit]

ASP; CPAMD1; Complement Protein C3; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1; C3a anaphylatoxin; Acylation stimulating protein

Complement Component 3 (C3)

Complement C3 is the major plasma proteins of the immune system complement pathways. The synthesis of these proteins is increased in response to inflammation and infection but at a slower rate than for traditional acute phase proteins. Complement protein C3 is the fourth component to attach in the complement reaction sequence. It is a beta-globulin with a sedimentation coefficient of 5.5 and a molecular weight of 185,000. C3 is a central molecule in the complement system whose activation is essential for all the important functions performed by this system. C3 can promote phagocytosis during an inflammatory response against pathogens, but unregulated activation of C3 could lead to host cell damage. Low level of serum C3 associates with hypocomplementaemia, primary biliary cirrhosis

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPA861Hu01 Recombinant Complement Component 3 (C3) Positive Control; Immunogen; SDS-PAGE; WB.
APA861Hu01 Active Complement Component 3 (C3) Cell culture; Activity Assays.
Antibodies PAA861Hu01 Polyclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC; IP; FCM
MAA861Hu22 Monoclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC; IP.
LAA861Hu71 Biotin-Linked Polyclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC.
LAA861Hu81 FITC-Linked Polyclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC; IF.
Assay Kits SEA861Hu ELISA Kit for Complement Component 3 (C3) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPA861Mu01 Recombinant Complement Component 3 (C3) Positive Control; Immunogen; SDS-PAGE; WB.
RPA861Mu02 Recombinant Complement Component 3 (C3) Positive Control; Immunogen; SDS-PAGE; WB.
APA861Mu01 Active Complement Component 3 (C3) Cell culture; Activity Assays.
Antibodies PAA861Mu01 Polyclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC; IP.
LAA861Mu71 Biotin-Linked Polyclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC.
LAA861Mu81 FITC-Linked Polyclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC; IF.
PAA861Mu02 Polyclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC; IP.
Assay Kits SEA861Mu ELISA Kit for Complement Component 3 (C3) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPA861Ra01 Recombinant Complement Component 3 (C3) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAA861Ra01 Polyclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC; IP.
LAA861Ra71 Biotin-Linked Polyclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC.
LAA861Ra81 FITC-Linked Polyclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC; IF.
MAA861Ra21 Monoclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC; IP.
Assay Kits SEA861Ra ELISA Kit for Complement Component 3 (C3) Enzyme-linked immunosorbent assay for Antigen Detection.
SCA861Ra CLIA Kit for Complement Component 3 (C3) Chemiluminescent immunoassay for Antigen Detection.

Organism species: Sus scrofa; Porcine (Pig)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPA861Po01 Recombinant Complement Component 3 (C3) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAA861Po01 Polyclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC; IP.
MAA861Po21 Monoclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC; IP.
Assay Kits SEA861Po ELISA Kit for Complement Component 3 (C3) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Bos taurus; Bovine (Cattle)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPA861Bo01 Recombinant Complement Component 3 (C3) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAA861Bo01 Polyclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC; IP.
Assay Kits SEA861Bo ELISA Kit for Complement Component 3 (C3) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Chicken (Gallus)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPA861Ga01 Recombinant Complement Component 3 (C3) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAA861Ga01 Polyclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC; IP.
MAA861Ga21 Monoclonal Antibody to Complement Component 3 (C3) WB; IHC; ICC; IP.
Assay Kits n/a CLIA Kit for Complement Component 3 (C3) CLIA Kit Customized Service Offer
n/a ELISA Kit for Complement Component 3 (C3) ELISA Kit Customized Service Offer
  1. "Human complement component C3: cDNA coding sequence and derived primary structure."Proc. Natl. Acad. Sci. U.S.A. 82:708-712(1985) [PubMed] [Europe PMC] [Abstract]
  2. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  3. "The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis."J. Clin. Invest. 92:1543-1547(1993) [PubMed] [Europe PMC] [Abstract]
  4. "Human anaphylatoxin (C3a) from the third component of complement. Primary structure."J. Biol. Chem. 250:8293-8301(1975) [PubMed] [Europe PMC] [Abstract]
  5. "Identification of angiotensinogen and complement C3dg as novel proteins binding the proform of eosinophil major basic protein in human pregnancy serum and plasma."J. Biol. Chem. 270:13645-13651(1995) [PubMed] [Europe PMC] [Abstract]
  6. "Third component of human complement: localization of the internal thiolester bond."Proc. Natl. Acad. Sci. U.S.A. 79:1054-1058(1982) [PubMed] [Europe PMC] [Abstract]
  7. "A 34-amino acid peptide of the third component of complement mediates properdin binding."J. Immunol. 140:1577-1580(1988) [PubMed] [Europe PMC] [Abstract]
  8. "Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2."Microb. Pathog. 3:423-435(1987) [PubMed] [Europe PMC] [Abstract]
  9. "Purification and characterization of acylation stimulating protein."J. Biol. Chem. 264:426-430(1989) [PubMed] [Europe PMC] [Abstract]
  10. "Structural requirements for thioester bond formation in human complement component C3. Reassessment of the role of thioester bond integrity on the conformation of C3."J. Biol. Chem. 267:10062-10069(1992) [PubMed] [Europe PMC] [Abstract]
  11. "Disulfide bridges in human complement component C3b."FEBS Lett. 315:85-90(1993) [PubMed] [Europe PMC] [Abstract]
  12. "Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line."Biochim. Biophys. Acta 1344:221-229(1997) [PubMed] [Europe PMC] [Abstract]
  13. "Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period."J. Lipid Res. 39:884-891(1998) [PubMed] [Europe PMC] [Abstract]
  14. "Acylation-stimulating protein (ASP): structure-function determinants of cell surface binding and triacylglycerol synthetic activity."Biochem. J. 342:41-48(1999) [PubMed] [Europe PMC] [Abstract]
  15. "The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des Arg(74)."J. Biol. Chem. 277:7165-7169(2002) [PubMed] [Europe PMC] [Abstract]
  16. "The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein."J. Biol. Chem. 278:11123-11129(2003) [PubMed] [Europe PMC] [Abstract]
  17. "Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry."Nat. Biotechnol. 21:660-666(2003) [PubMed] [Europe PMC] [Abstract]
  18. "Screening for N-glycosylated proteins by liquid chromatography mass spectrometry."Proteomics 4:454-465(2004) [PubMed] [Europe PMC] [Abstract]
  19. "Acylation-stimulating protein: effect of acute exercise and endurance training."Int. J. Obes. Relat. Metab. Disord. 29:632-638(2005) [PubMed] [Europe PMC] [Abstract]
  20. "C5L2 is a functional receptor for acylation-stimulating protein."J. Biol. Chem. 280:23936-23944(2005) [PubMed] [Europe PMC] [Abstract]
  21. "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry."J. Proteome Res. 4:2070-2080(2005) [PubMed] [Europe PMC] [Abstract]
  22. "Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes."Int. J. Obes. Relat. Metab. Disord. 30:439-446(2006) [PubMed] [Europe PMC] [Abstract]
  23. "Targeting the signaling pathway of acylation stimulating protein."J. Lipid Res. 47:643-652(2006) [PubMed] [Europe PMC] [Abstract]
  24. "Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach."Mol. Cell. Proteomics 5:226-233(2006) [PubMed] [Europe PMC] [Abstract]
  25. "Acylation stimulating protein but not complement C3 associates with metabolic syndrome components in Chinese children and adolescents."Eur. J. Endocrinol. 159:781-790(2008) [PubMed] [Europe PMC] [Abstract]
  26. "Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry."J. Proteome Res. 8:651-661(2009) [PubMed] [Europe PMC] [Abstract]
  27. "C5a- and ASP-mediated C5L2 activation, endocytosis and recycling are lost in S323I-C5L2 mutation."Mol. Immunol. 46:3086-3098(2009) [PubMed] [Europe PMC] [Abstract]
  28. "Mutational analyses reveal that the staphylococcal immune evasion molecule Sbi and complement receptor 2 (CR2) share overlapping contact residues on C3d: implications for the controversy regarding the CR2/C3d cocrystal structure."J. Immunol. 184:1946-1955(2010) [PubMed] [Europe PMC] [Abstract]
  29. "Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking."J. Mol. Biol. 404:697-710(2010) [PubMed] [Europe PMC] [Abstract]
  30. "Serum complement C3: a determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-aged population."Metabolism 59:628-634(2010) [PubMed] [Europe PMC] [Abstract]
  31. "Initial characterization of the human central proteome."BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract]
  32. "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome."J. Proteomics 96:253-262(2014) [PubMed] [Europe PMC] [Abstract]
  33. "Secondary structure of complement component C3a anaphylatoxin in solution as determined by NMR spectroscopy: differences between crystal and solution conformations."Proc. Natl. Acad. Sci. U.S.A. 85:5036-5040(1988) [PubMed] [Europe PMC] [Abstract]
  34. "X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2."Science 280:1277-1281(1998) [PubMed] [Europe PMC] [Abstract]
  35. "Structure of complement receptor 2 in complex with its C3d ligand."Science 292:1725-1728(2001) [PubMed] [Europe PMC] [Abstract]
  36. "Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study."J. Mol. Biol. 346:859-873(2005) [PubMed] [Europe PMC] [Abstract]
  37. "Structures of complement component C3 provide insights into the function and evolution of immunity."Nature 437:505-511(2005) [PubMed] [Europe PMC] [Abstract]
  38. "Structure of C3b reveals conformational changes that underlie complement activity."Nature 444:213-216(2006) [PubMed] [Europe PMC] [Abstract]
  39. "Structure of C3b in complex with CRIg gives insights into regulation of complement activation."Nature 444:217-220(2006) [PubMed] [Europe PMC] [Abstract]
  40. "Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition."J. Biol. Chem. 282:29241-29247(2007) [PubMed] [Europe PMC] [Abstract]
  41. "A structural basis for complement inhibition by Staphylococcus aureus."Nat. Immunol. 8:430-437(2007) [PubMed] [Europe PMC] [Abstract]
  42. "A structural basis for Staphylococcal complement subversion: X-ray structure of the complement-binding domain of Staphylococcus aureus protein Sbi in complex with ligand C3d."Mol. Immunol. 48:452-462(2011) [PubMed] [Europe PMC] [Abstract]
  43. "A crystal structure of the complex between human complement receptor 2 and its ligand C3d."Science 332:608-611(2011) [PubMed] [Europe PMC] [Abstract]
  44. "The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha-chain of the complement component, C3."J. Immunol. 143:1254-1258(1989) [PubMed] [Europe PMC] [Abstract]
  45. ErratumJ. Immunol. 143:3860-3862(1989) [PubMed] [Europe PMC] [Abstract]
  46. "Molecular basis of polymorphisms of human complement component C3."J. Exp. Med. 172:1011-1017(1990) [PubMed] [Europe PMC] [Abstract]
  47. "Inherited human complement C3 deficiency. An amino acid substitution in the beta-chain (Asp549 to Asn) impairs C3 secretion."J. Biol. Chem. 269:28494-28499(1994) [PubMed] [Europe PMC] [Abstract]
  48. "A novel C3 allotype C3'F02'has an amino acid substitution that may inhibit iC3b synthesis and cause C3-hypocomplementemia."Mol. Immunol. 30:62-62(1993)
  49. "Complement C3 variant and the risk of age-related macular degeneration."N. Engl. J. Med. 357:553-561(2007) [PubMed] [Europe PMC] [Abstract]
  50. "Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome." Blood 112:4948-4952(2008) [PubMed] [Europe PMC] [Abstract]
  51. "Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome."Hum. Mutat. 31:E1445-E1460(2010) [PubMed] [Europe PMC] [Abstract]
  52. "Quantitative detection of single amino acid polymorphisms by targeted proteomics."J. Mol. Cell Biol. 3:309-315(2011) [PubMed] [Europe PMC] [Abstract]
  53. "Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk."Proc. Natl. Acad. Sci. U.S.A. 108:8761-8766(2011) [PubMed] [Europe PMC] [Abstract]
  54. "Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration."Nat. Genet. 45:1366-1370(2013) [PubMed] [Europe PMC] [Abstract]